Fyrte avgårde denne til Egberts nå, helt uaktuelt dersom de tror at de kan slippe unna en call uten å fortelle hva som skjedde i Paradigme!
Good evening Jan,
I’m writing to you due to what is probably a misunderstanding somewhere in the communication lines.
As you are fully aware of the investors are still in shock after the very disappointing Paradigme update.
Data from the Lymrit 37-01 and half way through Paradigme when concluding that the company was very encouraged by the observations so far, it was not to believe that it seems like all the patients after the interim readout seemed to no longer have any effect of the treatment.
There has of course been speculations on what might have triggered this dramatic fall in efficacy, but speculations is not good enough for any shareholders. The investors / owners need to receive fact and answers to understand what has happened with their investments in Paradigme.
You raised money to fulfill Paradigme as late as february 2022, and there were no signs in the communication that you had observed any disappointing developements regarding levels of efficacy. The investormarket therefore provided you with yet another 250 MNOK. We were fully aware of the slow speed in recruitment, but did not receive any information that patients had stopped responding to this treatment.
Lately there have been talk about that Nordic Nanovector is not planning to give any update on feedbacks from the FDA regarding the path going forward for Betalutin, neither on what has led to the catastrophic development in efficacy. I hope this is heavily misunderstood by someone who has claimed that this is information is given by someone working in Nordic Nanovector. Not providing any information on what has happened with the 108 patients after the market has invested over 1 500 MNOK in the study would be a complete disaster and of course not accepted by the market.
We would need to know what has triggered the data and see behind it. This will be a must to understand the very optimistic guidance you have been given the market all the way until june 2022, and further to understand what are the assets you are bringing to the table when you have engaged Carnegie and Selmer to achieve an outcome that creates maximum value for shareholders. There are only some weeks ago we were told that the company would go forward with the remaining four other assets, now it seems that the company are heading towards an exit-strategy to return the best outcome for the shareholders. As a long term shareholder that has supported the company with funding I do appreciate that you have taken these measures to secure an outcome that might give us some payback on the investments, hopefully at another level pr share then the recent share price levels. But being able to accept and understand the next steps we would need to have decent information to react on.
I do understand that you will keep the details in the ongoing process of creating the best possible economic outcome behind closed walls until a solution is ready to be announced. I do also trust that data you are providing and sharing through this process is complete and with potenial attractive value for other pharma companies that migt be interested in going on with Archer, Alpha37,next genCar-T and so on. As such an update and explaination of what happend to the responders / patients in Paradigme is a complete must to fully understand how Betalutin possible could have a future in the NHL-market in the right combinations such as Archer, or in sub-populations.
I’m looking forward to the presentation to come on Wednesday, and urge you to respect the shareholders investments and need to understand what happened to the Betalutin-treated patients.
